CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

被引：191

作者：

Kuhn, Nicholas F. ^{[1
,2
]}

Purdon, Terence J. ^{[2
]}

van Leeuwen, Dayenne G. ^{[2
]}

Lopez, Andrea, V ^{[2
]}

Curran, Kevin J. ^{[3
]}

Daniyan, Anthony F. ^{[2
]}

Brentjens, Renier J. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA

来源：

CANCER CELL | 2019年 / 35卷 / 03期

基金：

美国国家卫生研究院;

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; DENDRITIC CELLS; B-CELLS; PHASE-I; EXPRESSION; ACTIVATION; CAR; MOUSE; IMMUNOTHERAPY; EFFICACY;

D O I：

10.1016/j.ccell.2019.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies. However, improved CAR T cell therapies are still needed. Here, we engineered tumor-targeted CAR T cells to constitutively express the immune-stimulatory molecule CD40 ligand (CD40L) and explored efficacy in differentmouse leukemia/ lymphoma models. We observed that CD40L(+) CAR T cells circumvent tumor immune escape via antigen loss through CD40/CD40L-mediated cytotoxicity and induction of a sustained, endogenous immune response. After adoptive cell transfer, the CD40L(+) CAR T cells displayed superior antitumor efficacy, licensed antigen-presenting cells, enhanced recruitment of immune effectors, and mobilized endogenous tumorrecognizing T cells. These effects were absent in Cd40(-/-) mice and provide a rationale for the use of CD40L(+) CAR T cells in cancer treatment.

引用

页码：473 / +

页数：22

共 58 条

[1] Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System [J].

Avanzi, Mauro P. ;

Yeku, Oladapo ;

Li, Xinghuo ;

Wijewarnasuriya, Dinali P. ;

van Leeuwen, Dayenne G. ;

Cheung, Kenneth ;

Park, Hyebin ;

Purdon, Terence J. ;

Daniyan, Anthony F. ;

Spitzer, Matthew H. ;

Brentjens, Renier J. .

CELL REPORTS, 2018, 23 (07) :2130-2141

[2] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[3] Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation [J].

Barbier, Louise ;

Tay, Szun Szun ;

McGuffog, Claire ;

Triccas, James A. ;

McCaughan, Geoffrey W. ;

Bowen, David G. ;

Bertolino, Patrick .

JOURNAL OF HEPATOLOGY, 2012, 57 (02) :352-358

[4] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].

Beatty, Gregory L. ;

Torigian, Drew A. ;

Chiorean, E. Gabriela ;

Saboury, Babak ;

Brothers, Alex ;

Alavi, Abass ;

Troxel, Andrea B. ;

Sun, Weijing ;

Teitelbaum, Ursina R. ;

Vonderheide, Robert H. ;

O'Dwyer, Peter J. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295

[5] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

[6] Toxicity and management in CAR T-cell therapy [J].

Bonifant, Challice L. ;

Jackson, Hollie J. ;

Brentjens, Renier J. ;

Curran, Kevin J. .

MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16011

[7] Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human [J].

Bossen, Claudia ;

Ingold, Karine ;

Tardivel, Aubry ;

Bodmer, Jean-Luc ;

Gaide, Olivier ;

Hertig, Sylvie ;

Ambrose, Christine ;

Tschopp, Juerg ;

Schneider, Pascal .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (20) :13964-13971

[8] A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory [J].

Bourgeois, C ;

Rocha, B ;

Tanchot, C .

SCIENCE, 2002, 297 (5589) :2060-2063

[9] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].

Brentjens, RJ ;

Latouche, JB ;

Santos, E ;

Marti, F ;

Gong, MC ;

Lyddane, C ;

King, PD ;

Larson, S ;

Weiss, M ;

Rivière, I ;

Sadelain, M .

NATURE MEDICINE, 2003, 9 (03) :279-286

[10] Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice [J].

Brown, MP ;

Topham, DJ ;

Sangster, MY ;

Zhao, JF ;

Flynn, KJ ;

Surman, SL ;

Woodland, DL ;

Doherty, PC ;

Farr, AG ;

Pattengale, PK ;

Brenner, MK .

NATURE MEDICINE, 1998, 4 (11) :1253-1260

← 1 2 3 4 5 6 →